Immunotherapy News and Research

Latest Immunotherapy News and Research

Mother's illness, allergen exposure during pregency may predict child's risk of asthma and allergy

Women that are pregnant may want to take extra precaution around those that are sniffling and sneezing this winter. According to a new study published today, the more common colds and viral infections a woman has during pregnancy, the higher the risk her baby will have asthma.

4 Feb 2014

Children newly diagnosed with Crohn's disease may benefit from biologic drugs

Children newly diagnosed with Crohn's disease may benefit from early treatment with the biologic drugs known as anti-TNF-α agents, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.

3 Feb 2014

Treating peanut allergy with oral immunotherapy changes DNA of immune cells

Treating a peanut allergy with oral immunotherapy changes the DNA of the patient's immune cells, according to a new study from the Stanford University School of Medicine and Lucile Packard Children's Hospital Stanford. The DNA change could serve as the basis for a simple blood test to monitor the long-term effectiveness of the allergy therapy.

31 Jan 2014

Children with peanut allergies could benefit from oral immunotherapy treatment

Children and adolescents with peanut allergies could benefit from treatment with oral immunotherapy (OIT), in which peanut protein is consumed in increasingly larger amounts on a regular basis to build up tolerance, according to a phase 2 trial published in The Lancet.

31 Jan 2014

Vaccine to treat precancerous cervical lesions triggers immune cell response

Preliminary results of a small clinical trial show that a vaccine used to treat women with high-grade precancerous cervical lesions triggers an immune cell response within the damaged tissue itself.

30 Jan 2014

Researchers find novel drug combination approach to speed fight against cancer

Cancer is the leading cause of death in Canada and is responsible for about 30% of all deaths, according to the Canadian Cancer Society. Despite the urgent need for new and effective drugs, it remains extremely difficult to develop anti-cancer therapies in a timely way.

27 Jan 2014

Immunotherapy maintenance shows promise in NSCLC

Results from a phase III trial have shown that tecemotide is no more effective than placebo as maintenance therapy in patients with non-small-cell lung cancer.

24 Jan 2014

FDA to make recommendations on safety of oral tablets used to treat ragweed allergy symptoms

There is more to seasonal allergies than a little congestion and sneezing. If you notice eating watermelon, cantaloupe or avocado make you cough and itch, it may be a symptom of ragweed allergy. But more help might be on the way for some of the 23 million hay fever sufferers.

24 Jan 2014

Inovio Pharmaceuticals unveils new DNA-based cytokine immune activator

Inovio Pharmaceuticals, Inc. today unveiled that the company has developed a new DNA-based cytokine immune activator, interleukin -33 (IL-33), that in combination with optimized DNA vaccines delivered by electroporation increased the potency and efficacy of the therapeutic response to the DNA vaccines in a preclinical study.

23 Jan 2014

Personalized vaccine therapy contributes to increased survival rate in IL2-treated metastatic melanoma

Metastatic melanoma has a poor prognosis, but treatment with high-dose interleukin-2 (IL2) can extend survival. Now, a combination of IL2 therapy and activation of patients' immune systems using personalized vaccines made from their own tumor cells has been shown to improve survival rates even more than IL2 alone, according to a new article in Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

23 Jan 2014

MD Anderson collaborates with Johnson & Johnson to develop immunology-based cancer treatments

The University of Texas MD Anderson Cancer Center will collaborate with Johnson & Johnson Innovation, LLC, and its affiliate Janssen Biotech, Inc., to develop immunology-based cancer treatments through the MD Anderson Moon Shots Program immunotherapy platform.

23 Jan 2014

Advanced melanoma treatments: an interview with Dr. James Larkin, Consultant Medical Oncologist, The Royal Marsden

Advanced melanoma affects around 2,000 people per year in the UK. Advanced melanoma describes a melanoma that has spread from its site of origin to other areas of the body.

22 Jan 2014

First patient dosed in ADXS-HPV Phase 1/2 study for HPV-associated head and neck cancer

Advaxis, Inc., a leader in developing the next generation of cancer immunotherapies, announced that the first patient has been dosed in a Phase 1/2 "window of opportunity" study being conducted by the Icahn School of Medicine at Mount Sinai. Patients diagnosed with HPV-associated head and neck cancer will receive ADXS-HPV immunotherapy during the "window" of time between initial diagnosis and minimally invasive transoral robotic surgery to remove their tumors.

21 Jan 2014

Researchers develop 3 hypoallergenic variants of Pru p 3 protein

A research conducted by the Centre for Plant Biotechnology and Genomics (UPM-INIA) and led by Araceli Díaz Perales has studied the allergy to peach, the most common food allergy, and the Pru p 3 protein. As a result of this research work, they have developed three hypoallergenic variants of this protein. All can be good candidates for the usage of specific immunotherapy for peach allergy and also can be used as a vaccine.

20 Jan 2014

Three new spin-offs emerged from Helmholtz Zentrum München

Three new spin-offs emerged from Helmholtz Zentrum München (HMGU) in 2013: SurgVision, Trianta Immunotherapies and Dosimetrics. Thanks to successful innovation management, the Center has transformed excellent research findings into practical applications and given new impulses to the areas of clinical imaging, immunotherapy and radiation dosimetry.

17 Jan 2014

Biothera enhances innate immune responses to Imprime PGG drug candidate

Biothera has enhanced innate immune responses to its cancer immunotherapy drug candidate Imprime PGG in subjects regardless of biomarker status, demonstrating the opportunity to treat a larger patient population. The in vitro research will be presented today at the Cambridge Healthtech Institute's Antibody-Drug Conjugates/Engineering Targeted Therapeutics conference in Palm Springs, CA.

16 Jan 2014

Research reveals new therapy for preventing production of sphingolipids by lymphoma cells

Christopher Parsons, MD, Director of the HIV Malignancies Program at LSU Health Sciences Center New Orleans, is the senior author of a paper that is the first to report that specialized fat (lipid) molecules, called sphingolipids, play a key role in the survival of aggressive lymphomas caused by viruses.

15 Jan 2014

Patient's own bone-marrow stromal cells could treat multi-drug resistant TB

Findings of a preliminary study published in The Lancet Respiratory Medicine suggest that a patient’s own bone-marrow stromal (stem) cells could be used to treat multidrug-resistant (MDR) and extensively-drug (XDR) tuberculosis.

10 Jan 2014

Researchers develop personalized tool to predict likelihood of prostate cancer overdiagnosis

Studies have found that prostate cancer is overdiagnosed in up to 42 percent of cases, prompting men to receive unnecessary treatment that can cause devastating side effects, including impotence and incontinence.

9 Jan 2014

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Biothera today reported positive results from its proof of concept Phase 2 clinical trial in 90 patients with advanced non-small cell lung cancer (NSCLC) at the American Association for Cancer Research and the International Association for the Study of Lung Cancer joint conference on the Molecular Origins of Lung Cancer in San Diego.

8 Jan 2014

Immunotherapy News and Research

Latest Immunotherapy News and Research

Mother's illness, allergen exposure during pregency may predict child's risk of asthma and allergy

Children newly diagnosed with Crohn's disease may benefit from biologic drugs

Treating peanut allergy with oral immunotherapy changes DNA of immune cells

Children with peanut allergies could benefit from oral immunotherapy treatment

Vaccine to treat precancerous cervical lesions triggers immune cell response

Researchers find novel drug combination approach to speed fight against cancer

Immunotherapy maintenance shows promise in NSCLC

FDA to make recommendations on safety of oral tablets used to treat ragweed allergy symptoms

Inovio Pharmaceuticals unveils new DNA-based cytokine immune activator

Personalized vaccine therapy contributes to increased survival rate in IL2-treated metastatic melanoma

MD Anderson collaborates with Johnson & Johnson to develop immunology-based cancer treatments

Advanced melanoma treatments: an interview with Dr. James Larkin, Consultant Medical Oncologist, The Royal Marsden

First patient dosed in ADXS-HPV Phase 1/2 study for HPV-associated head and neck cancer

Researchers develop 3 hypoallergenic variants of Pru p 3 protein

Three new spin-offs emerged from Helmholtz Zentrum München

Biothera enhances innate immune responses to Imprime PGG drug candidate

Research reveals new therapy for preventing production of sphingolipids by lymphoma cells

Patient's own bone-marrow stromal cells could treat multi-drug resistant TB

Researchers develop personalized tool to predict likelihood of prostate cancer overdiagnosis

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Event guide: 7th Allogeneic Cell Therapies Summit eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Immunotherapy News and Research

Latest Immunotherapy News and Research

Event guide: 7th Allogeneic Cell Therapies Summit eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in